LENZ Therapeutics, Inc.
LENZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12,500 | $5,000 | $0 | $0 |
| % Growth | 150% | – | – | – |
| Cost of Goods Sold | $125 | $0 | $0 | $0 |
| Gross Profit | $12,375 | $5,000 | $0 | $0 |
| % Margin | 99% | 100% | – | – |
| R&D Expenses | $3,791 | $9,061 | $5,818 | $5,868 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $27,471 | $12,796 | $11,113 | $9,357 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $31,262 | $21,857 | $16,931 | $15,225 |
| Operating Income | -$18,887 | -$16,857 | -$16,931 | -$15,225 |
| % Margin | -151.1% | -337.1% | – | – |
| Other Income/Exp. Net | $2,187 | $2,445 | $2,312 | $2,574 |
| Pre-Tax Income | -$16,700 | -$14,412 | -$14,619 | -$12,651 |
| Tax Expense | $0 | $500 | $0 | $1 |
| Net Income | -$16,700 | -$14,912 | -$14,619 | -$12,652 |
| % Margin | -133.6% | -298.2% | – | – |
| EPS | -0.59 | -0.53 | -0.53 | -0.46 |
| % Growth | -11.3% | 0% | -15.2% | – |
| EPS Diluted | -0.59 | -0.53 | -0.53 | -0.46 |
| Weighted Avg Shares Out | 28,541 | 28,079 | 27,526 | 27,493 |
| Weighted Avg Shares Out Dil | 28,541 | 28,079 | 27,526 | 27,493 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,201 | $2,246 | $2,323 | $2,566 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $125 | $19 | $36 | $25 |
| EBITDA | -$16,575 | -$16,838 | -$16,895 | -$15,200 |
| % Margin | -132.6% | -336.8% | – | – |